Actively Recruiting
Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
Led by Jiangsu vcare pharmaceutical technology co., LTD · Updated on 2025-02-11
480
Participants Needed
1
Research Sites
139 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study
CONDITIONS
Official Title
Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient understands and voluntarily signs informed consent and can complete all study visits, treatments, lab tests, and procedures
- Male or female patients aged 18 to 75 years at time of consent
- Meets Hanifin-Rajka diagnostic criteria and has had atopic dermatitis symptoms for at least 1 year before baseline
- At screening and baseline, has moderate to severe atopic dermatitis with EASI score ≥12, IGA score ≥3, and involvement of ≥10% body surface area
- Had recent topical treatment for atopic dermatitis within 1 year before screening with inadequate or intolerant clinical response
You will not qualify if you...
- Unable to swallow the study drug or has gastrointestinal disorders affecting drug absorption such as Crohn's disease, ulcerative colitis, or malabsorption conditions
- Current or history of lymphoproliferative disorders, lymphadenopathy, splenomegaly, any malignancy within 5 years prior to screening except certain skin or thyroid cancers
- History of thromboembolism or high risk for thromboembolism
- History of herpes virus infection within last month or recurrent herpes zoster or herpes simplex infections, or current herpes infections cannot be excluded
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese Academy of Medical Sciences Hospital for Skin Diseases
Nanjing, Jiangsu, China, 210042
Actively Recruiting
Research Team
X
xiaojuan Lai
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here